Stockscreener 앱 받기
2.95
4.47%
-0.18
시간 외 거래:
3.03
0.08
+2.71%
전일 마감가:
$3.13
열려 있는:
$3.18
하루 거래량:
230.27K
Relative Volume:
0.39
시가총액:
$24.74M
수익:
$1.73M
순이익/손실:
$-23.50M
주가수익비율:
-0.6753
EPS:
-4.3682
순현금흐름:
$-19.37M
1주 성능:
+27.23%
1개월 성능:
+6.71%
6개월 성능:
-51.98%
1년 성능:
-71.00%
1일 변동 폭
$2.81
$3.20
1주일 범위
$2.35
$3.26
52주 변동 폭
$1.906
$18.80
VolitionRX Ltd Stock (VNRX) Company Profile
명칭
VolitionRX Ltd
전화
646 650 1351
주소
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, IDXX, WAT, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
2.97 | 26.07M | 1.73M | -23.50M | -19.37M | -4.3682 |
TMO
Thermo Fisher Scientific Inc
|
448.27 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.86 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.15 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
338.72 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.09 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | H.C. Wainwright | Buy |
| 2023-02-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 개시 | Maxim Group | Buy |
| 2018-05-14 | 재확인 | The Benchmark Company | Buy |
| 2016-09-07 | 재확인 | Rodman & Renshaw | Buy |
| 2016-02-01 | 개시 | Rodman & Renshaw | Buy |
모두보기
VolitionRX Ltd 주식(VNRX)의 최신 뉴스
VolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts - Yahoo Finance UK
VolitionRx Limited Files Form 8-K With SEC Detailing Company Information and NYSE Listing - Minichart
VolitionRx receives waiver on market capitalization covenant from Lind Global - Investing.com
VolitionRx Obtains Covenant Waiver on $9.9 Million Convertible Notes From Lind, Avoiding Acceleration - TradingView
Covenant breach leads VolitionRx (NYSE: VNRX) to secure Lind waiver and note changes - Stock Titan
VNRX Technical Analysis | Trend, Signals & Chart Patterns | VOLITIONRX LTD (NYSEARCA:VNRX) - ChartMill
VolitionRX Earnings Call: Breakthrough Science, Cash Burn Risk - TipRanks
VolitionRX Earnings Call Balances Breakthroughs and Risks - TipRanks
VolitionRx Limited (AMEX:VNRX) Q1 2026 Earnings Call Transcript - Insider Monkey
VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Partnerships Propel Growth - GuruFocus
VolitionRx director Mickie Henshall to step down, board size to be reduced - Investing.com Australia
VolitionRx director Mickie Henshall to step down, board size to be reduced By Investing.com - Investing.com South Africa
Mickie Henshall to Leave Volition Board; Company to Reduce Board Size - TradingView
VolitionRx (VNRX) director exits at 2026 meeting as board shrinks to seven - Stock Titan
Lagoda holds 17.07M VolitionRX shares after amendment (VNRX) - Stock Titan
Earnings call transcript: VolitionRx Q1 2026 sees revenue surge, EPS miss - Investing.com
Full Transcript: VolitionRX Q1 2026 Earnings Call - Benzinga
Q1 2026 VolitionRX Ltd Earnings Call Transcript - GuruFocus
VolitionRx : Short Corporate Deck, May 2026 - marketscreener.com
Is VolitionRX (VNRX) a Value Trap After Q1 2026? EPS Not Disclos - GuruFocus
VolitionRX: Q1 Earnings Snapshot - marketscreener.com
VolitionRx Ltd stock (US92852X1037): Q1 2026 update and epigenetics business profile - AD HOC NEWS
Rising revenue but cash risk at VolitionRx (NYSE: VNRX) in Q1 2026 - Stock Titan
VolitionRx (NYSE: VNRX) lifts Q1 2026 revenue and secures new funding - Stock Titan
Cat cancer blood test may unlock $5M payout for VolitionRx - Stock Titan
VolitionRX Q1 2026 Earnings Call Transcript - MarketBeat
VolitionRx (VNRX) seeks approval to cut authorized shares and adopt 2026 equity plan - Stock Titan
TradingKey - TradingKey
Earnings Preview: VolitionRX to Report Financial Results Pre-market on May 15 - Moomoo
Press Release: VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update - Moomoo
What to expect from VolitionRx’s May 15 Q1 2026 earnings call - Stock Titan
MSN Money - MSN
VolitionRx (VNRX) Advances Feline Cancer Detection Research with New Submission - GuruFocus
BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Reports High Accuracy In Feline Cancer Blood Test Study - StreetInsider
A blood test for cat lymphoma showed 86% detection at 97% specificity - Stock Titan
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats - Financial Times
User - The Chronicle-Journal
VolitionRx Limited 2025 Annual Report: Executive Compensation, Director Ownership, and Corporate Governance Insights - Minichart
VNRX Stock Price, Quote & Chart | VOLITIONRX LTD (NYSEARCA:VNRX) - ChartMill
VolitionRX Limited (VNRX) Investment Case | Q4 2025: Earnings UnderperformEV/EBITDA - Newser
VolitionRX | 10-K/A: Annual report (Amendment) - Moomoo
CEO pay, board changes and reverse split at VolitionRx (NYSE: VNRX) - Stock Titan
VolitionRx (VNRX) Achieves Breakthrough in Sepsis Detection with New Test - GuruFocus
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing - Barchart.com
VolitionRx Limited Announces Amendment to Certificate of Incorporation in April 2026 8-K Filing - Minichart
VolitionRx (NYSE: VNRX) implements 1-for-20 reverse stock split - Stock Titan
DISCLOSED: 5 Stocks Congress Just Bought (PC6HZG2Kcg) - Fathom Journal
Is VolitionRX Limited (VNRX) stock forming a clear pattern | Q4 2025: EPS Misses EstimatesFCF Yield - newser.com
VolitionRX | 8-K: Current report - Moomoo
Trade VNRX - Intellectia AI
VolitionRx receives NYSE American compliance plan approval By Investing.com - Investing.com Australia
VolitionRX Ltd (VNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.43%
0.39%
자본화:
|
볼륨(24시간):